Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935282 · ClinicalTrials.gov registry record · NA
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
A NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 12
- Study locations
NCT03935282 is a NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 600 participants, above the 146-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (311% higher). The trial reports 12 study locations across 8 states.
The verdict
NCT03935282, a NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 12
- Study locations
Study Summary
The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in community oncology practices, using a group-randomized trial design (6 intervention practices and 6 usual care practices). Our central hypothesis is that the AH-HA tool will increase (1) cardiovascular health (CVH) discussions among survivors and oncology providers, (2) referrals and visits to primary care and cardiology (care coordination), and (3) cardiovascular (CV) risk reduction and health promotion activities compared to usual care.
Conditions Studied
Interventions
- OTHER AH-HA Tool in the EPIC EHR
Study Locations (12)
Missouri
- Saint Louis Cancer and Breast Institute-Ballwin - Ballwin
- Mercy Hospital Springfield - Springfield
- Mercy Hospital Saint Louis - St Louis
Pennsylvania
- Community Medical Center - Scranton
- Geisinger Wyoming Valley/Henry Cancer Center - Wilkes-Barre
Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis - Memphis
- Baptist Memorial Hospital for Women - Memphis
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Iowa
- Oncology Associates at Mercy Medical Center - Cedar Rapids
Oklahoma
- Mercy Hospital Oklahoma City - Oklahoma City
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Wisconsin
- ThedaCare Regional Cancer Center - Appleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-11-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935282
The ClinicalTrials.gov registry entry for NCT03935282 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (311% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AH-HA Tool in the EPIC EHR is the first listed.
NCT03935282 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Missouri, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03935282 about?
NCT03935282 is a clinical study titled "Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors". The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in commun...
What is the current status of trial NCT03935282?
This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2020-10-01. Estimated completion is 2025-11-17.
What conditions does trial NCT03935282 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Colorectal Neoplasms, Breast Neoplasm, Hodgkin Disease, Endometrial Neoplasms.
What interventions are being tested in trial NCT03935282?
The interventions under investigation include: AH-HA Tool in the EPIC EHR (OTHER).
Who is sponsoring clinical trial NCT03935282?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935282 being conducted?
This trial has 12 study locations across Arkansas, Iowa, Missouri, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
ACTIVE NOT RECRUITING · NA
-
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · NA
-
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
COMPLETED · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.